Dr. Shuyao Lang is currently an Associate Professor at Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences. She received her B.S. in Chemistry from the Special Class of the Gifted Young, University of Science and Technology of China (2009–2013), and her Ph.D. in Chemistry from Michigan State University (2013–2021) under the supervision of Prof. Xuefei Huang, focusing on chemical-immunological cross-disciplinary research.
Her research is dedicated to understanding the formation and remodeling of the tumor immunosuppressive microenvironment and developing novel cancer immunotherapies through the lens of chemical biology. She has made significant contributions on the investigation of biomedical polymer materials for cancer immunotherapy application. She developed myeloid-targeting peptide nanoparticles of silencing c-Rel myeloid immune checkpoint for enhanced anti-caner therapy (Frontiers in Immunology, 2025). She also developed a glycoengineering strategy for modifying natural killer cells with CD22 ligands, which enhanced NK cell specific killing against CD22+ B-cell lymphoma (ACS Central Science, 2020, cover article).
Research key words: cancer immunotherapy; biomedical polymers; tumor microenvironment; stimuli-responsive materials; cancer vaccines; MDSCs; gene therapy.
Dr. Shuyao Lang is currently an Associate Professor at Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences. She received her B.S. in Chemistry from the Special Class of the Gifted Young, University of Science and Technology of China (2009–2013), and her Ph.D. in Chemistry from Michigan State University (2013–2021) under the supervision of Prof. Xuefei Huang, focusing on chemical-immunological cross-disciplinary research.
Her research is dedicated to understanding the formation and remodeling of the tumor immunosuppressive microenvironment and developing novel cancer immunotherapies through the lens of chemical biology. She has made significant contributions on the investigation of biomedical polymer materials for cancer immunotherapy application. She developed myeloid-targeting peptide nanoparticles of silencing c-Rel myeloid immune checkpoint for enhanced anti-caner therapy (Frontiers in Immunology, 2025). She also developed a glycoengineering strategy for modifying natural killer cells with CD22 ligands, which enhanced NK cell specific killing against CD22+ B-cell lymphoma (ACS Central Science, 2020, cover article).
Research key words: cancer immunotherapy; biomedical polymers; tumor microenvironment; stimuli-responsive materials; cancer vaccines; MDSCs; gene therapy.